Welcome to the UPF Digital Repository

Plasma Concentrations of BDNF and IGF-1 in Abstinent Cocaine Users with High Prevalence of Substance Use Disorders: Relationship to Psychiatric Comorbidity

Show simple item record

dc.contributor.author Pedraz, María
dc.contributor.author Martín Velasco, Ana Isabel
dc.contributor.author García Marchena, Nuria
dc.contributor.author Araos, Pedro
dc.contributor.author Serrano, Antonia
dc.contributor.author Romero Sanchiz, Pablo
dc.contributor.author Suárez, Juan
dc.contributor.author Castilla Ortega, Estela
dc.contributor.author Barrios, Vicente
dc.contributor.author Campos Cloute, Rafael
dc.contributor.author Ruiz, Juan Jesús
dc.contributor.author Torrens, Marta
dc.contributor.author Chowen, Julie A.
dc.contributor.author Argente, Jesús
dc.contributor.author Torre Fornell, Rafael de la
dc.contributor.author Santín, Luis Javier
dc.contributor.author Villanúa, María Ángeles
dc.contributor.author Rodríguez de Fonseca, Fernando
dc.contributor.author Pavón, Francisco Javier
dc.date.accessioned 2015-03-26T13:04:28Z
dc.date.available 2015-03-26T13:04:28Z
dc.date.issued 2015
dc.identifier.citation Pedraz M, Martín-Velasco AI, García-Marchena N, Araos P, Serrano A, Romero-Sanchiz P,et al. Plasma Concentrations of BDNF and/nIGF-1 in Abstinent Cocaine Users with High Prevalence of Substance Use Disorders: Relationship to Psychiatric Comorbidity. PLoS ONE. 2015;10(3):e0118610. DOI: 10.1371/journal.pone.0118610
dc.identifier.issn 1932-6203
dc.identifier.uri http://hdl.handle.net/10230/23293
dc.description.abstract Recent studies have identified biomarkers related to the severity and pathogenesis of cocaine addiction and common comorbid psychiatric disorders. Monitoring these plasma mediators may improve the stratification of cocaine users seeking treatment. Because the neurotrophic factors are involved in neural plasticity, neurogenesis and neuronal survival, we have determined plasma concentrations of brain-derived neurotrophic factor (BDNF), insulin-like growth factor 1 (IGF-1) and IGF-1 binding protein 3 (IGFBP-3) in a cross-sectional study with abstinent cocaine users who sought outpatient treatment for cocaine (n = 100) and age/body mass matched controls (n = 85). Participants were assessed with the diagnostic interview 'Psychiatric Research Interview for Substance and Mental Disorders'. Plasma concentrations of these peptides were not different in cocaine users and controls. They were not associated with length of abstinence, duration of cocaine use or cocaine symptom severity. The pathological use of cocaine did not influence the association of IGF-1 with age observed in healthy subjects, but the correlation between IGF-1 and IGFBP-3 was not significantly detected. Correlation analyses were performed between these peptides and other molecules sensitive to addiction: BDNF concentrations were not associated with inflammatory mediators, lipid derivatives or IGF-1 in cocaine users, but correlated with chemokines (fractalkine/CX3CL1 and SDF-1/CXCL12) and N-acyl-ethanolamines (N-palmitoyl-, N-oleoyl-, N-arachidonoyl-, N-linoleoyl- and N-dihomo-γ-linolenoyl-ethanolamine) in controls; IGF-1 concentrations only showed association with IGFBP-3 concentrations in controls; and IGFBP-3 was only correlated with N-stearoyl-ethanolamine concentrations in cocaine users. Multiple substance use disorders and life-time comorbid psychopathologies were common in abstinent cocaine users. Interestingly, plasma BDNF concentrations were exclusively found to be decreased in users diagnosed with both primary and cocaine-induced disorders for mood and anxiety disorders. In summary, BDNF, IGF-1 and IGFBP-3 were not affected by a history of pathological use of cocaine supported by the absence of associations with other molecules sensitive to cocaine addiction. However, BDNF was affected by comorbid mood disorders. Further research is necessary to elucidate the role of BDNF and IGF-1 in the transition to cocaine addiction and associated psychiatric comorbidity.
dc.description.sponsorship The present study has been supported byInstituto de Salud Carlos III (ISC-III), Red deTrastornos Adictivos UE-FEDER 2012 (RD12/0028);Ministerio de Economía y Competitividad (PI13/02261); Plan Nacional sobre Drogas 049/2009 and049/2013; Consejería de Economía, Innovación yCiencia, Junta de Andalucía UE-FEDER (CTS-433);Consejería de Salud y Bienestar Social, Junta Andalucía (PI0228-2013 and PI0823-2012);Departament d’Innovació, Universitats i Empresa,Generalitat de Catalunya (2014-SGR-680). JS, ASand FJP hold a“Miguel Servet”research contractfrom ISC-III (CP12/03109, CP14/00173 and CP14/00212, respectively). PR-S holds a“Río Hortega”research contract from ISC-III (CM13/0115). EC-Oholds a“Sara Borrell”research contract from ISC-III(CD12/00455). The funders had no role in studydesign, data collection and analysis, decision topublish, or preparation of the manuscript.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Public Library of Science
dc.relation.ispartof PLoS ONE. 2015;10(3):e0118610
dc.rights © 2015 Pedraz et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.subject.other Psiquiatria
dc.subject.other Cocaïna
dc.subject.other Drogoaddicció
dc.title Plasma Concentrations of BDNF and IGF-1 in Abstinent Cocaine Users with High Prevalence of Substance Use Disorders: Relationship to Psychiatric Comorbidity
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1371/journal.pone.0118610
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

In collaboration with Compliant to Partaking